RxDoctor Payments Data

Seeth Vivek, MD

Psychiatry · Jamaica, NYNPI 1568404010

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 46.4% of the total. Reporting peaked in 2021 at $1,123 and has fallen 89.4% since, to $119 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,287in general payments, 2019–2025

Across 94 payments — averaging $45.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$2K
  • Alkermes, Inc.$603
  • AbbVie$465
  • Sunovion Pharmaceuticals Inc.$342
  • Teva Pharmaceuticals USA, Inc.$214
  • Johnson & Johnson$197
  • plus $478 from 6 others
$1,500in research payments, 2019–2025

Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$2K

What the payments were for

  • Food & beverage$4,287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,287 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Medicare billing

Part B allowed, 2024
$23,461
Medicare patients
18
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ziprasidone Hcl12$673
Alprazolam79$593
Escitalopram Oxalate38$448
Lorazepam27$364
Zolpidem Tartrate ErZolpidem Tartrate12$316
Memantine Hcl16$258
Citalopram HbrCitalopram Hydrobromide22$180
Bupropion XlBupropion Hcl11$175
Clonazepam35$175
Trazodone Hcl40$140
Divalproex Sodium12$128
Lamotrigine12$91
Paroxetine Hcl11$63
Fluoxetine Hcl16$49

Paid to pharmacies, not to this prescriber.

Other psychiatry in Jamaica

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →